StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
BKHA

Black Hawk Acquisition Corporation

BKHAR Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗
$1.70
+0.00 0.00%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
$7.06M
Revenue (TTM) ⓘ
—
Net income (TTM) ⓘ
$379K
EPS (TTM) ⓘ
—
P/E ratio ⓘ
—
Dividend yield ⓘ
—
Free cash flow ⓘ
—
Cash ⓘ
$0.00
Total assets ⓘ
$25.4M
Gross margin ⓘ
—
52-week range ⓘ
$1.70 – $1.70

AI briefing

from the latest 10-K, 10-Q and 8-K events

Black Hawk Acquisition Corp is a blank-check special purpose acquisition company (SPAC) formed to effect a merger or acquisition, with no operating business.

What they do

Black Hawk Acquisition Corp is a Cayman Islands-incorporated SPAC that raised proceeds through an initial public offering and holds those funds in a trust account. The company has no operations and its sole business purpose is to identify and complete an initial business combination, although it has not yet consummated one. It lists on the Nasdaq Global Market under the tickers BKHAU, BKHA, and BKHAR for units, ordinary shares, and rights, respectively.

Revenue drivers

  • Interest income on trust account — The company's only income comes from interest earned on the investments held in its trust account, which totaled $25.3 million as of May 31, 2026.
  • Initial public offering proceeds — The trust account is funded by IPO proceeds, and the company does not generate revenue from operations.

Recent performance

For the fiscal year ended November 30, 2025, the company reported a net income of $1.3 million, down from $1.9 million in 2024, while operating cash flow was negative $650,321 in 2025 versus negative $553,665 in 2024. As of May 31, 2026, total assets were $25.4 million, including $25.3 million in trust investments, with total liabilities of $5.2 million and a shareholders' deficit of $5.1 million. Cash and equivalents were $11,583, and the company had issued and outstanding 4,153,577 ordinary shares as of July 15, 2026.

Strategy

Management states its primary strategy is to identify and complete an initial business combination, though no specific target has been announced. The company has entered into material agreements and taken on direct financial obligations, as disclosed in 8-K filings, including a due-to-target company liability of $1.3 million as of May 31, 2026. It also adopted an Incentive Compensation Recovery (Clawback) Policy, as disclosed in the 10-K/A. The company is actively seeking a target and has engaged in related-party transactions, such as a due-to-related-party balance of $7,400.

Risks

  • Failure to complete a business combination — If the company does not complete a business combination within the required timeframe, it may be forced to liquidate and return trust proceeds to shareholders, resulting in no return for investors.
  • Delisting or listing-rule failure — An 8-K filed on 2026-04-01 indicates the company received a delisting notice or failed to meet a listing rule, which could affect its ability to trade on Nasdaq.
  • Negative shareholders' equity — The company reported a shareholders' deficit of $5.1 million, indicating accumulated losses and potential going-concern issues.
  • Dependence on target company financing — The company has a due-to-target company liability of $1.3 million, suggesting it may have incurred costs related to a potential target, which could be at risk if a deal fails.

Outlook

Management has not provided a specific forward-looking outlook beyond pursuing an initial business combination. The company continues to hold trust funds and incur operating expenses, with operating cash flow negative in both 2024 and 2025. No definitive acquisition agreement has been announced as of the latest filing.

Recent SEC filings

40 most recent
Annual, quarterly & current reports